Cor Vasa 2009, 51(2):119-122 | DOI: 10.33678/cor.2009.029
Treatment of dyslipidemia after myocardial infarction
- Oddělení klinické biochemie, Fakultní nemocnice u sv. Anny v Brně a Lékařská fakulta Masarykovy univerzity, Brno, Česká republika
Lipid-lowering drugs, and statins in particular, are the mainstay of treatment in myocardial infarction survivors. Statins are indicated in post-MI patients whose LDL-cholesterol levels are above the target; treatment should be initiated already during hospitalization. Fibrates are indicated in the combination with statins in patients with low HDL-cholesterol levels and/or increased triglyceride levels persisting while on statins. Lipid-lowering therapy should be always combined with non-pharmacological treatment, i.e., lifestyle modifications. Every effort should be made to reach target LDL-cholesterol levels as well as optimal triglyceride and HDL-cholesterol levels. Treatment should be uninterrupted, it is not advisable to discontinue it. Regular monitoring of laboratory values is critical, especially upon lipid-lowering therapy initiation.
Keywords: Myocardial infarction; Dyslipidemia; Statins; Ezetimibe; Fibrates
Published: February 1, 2009 Show citation
References
- Collins R, Armitage J, Parish S, et al. (Heart Protection Study Collaborative Group). MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
Go to original source... 
Go to PubMed... - Nissen SE, Tuzcu EM, Schoenhagen P, et al. (REVERSAL Investigators). Effect of intensive compared with moderate lipid-lowering therapy on pregression of coronary atherosclerosis. A randomized controlled trial. JAMA 2004;291:1071-80. Go to original source... Go to PubMed...
- Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis: The ASTEROID Trial. JAMA 2006; Mar 13: [Epub ahead of print]. Go to original source... Go to PubMed...
- Grundy SM, Cleeman JI, Merz NB, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-39. Go to original source... Go to PubMed...
- Graham I, Atar D, Borch-Johansen K, et al. European guidelines fo cardiovascular disease prevention in clinical practice: Executive summary. Atherosclerosis 2007;194:1-45. Go to original source... Go to PubMed...
- Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-8. Go to original source... Go to PubMed...
- Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-33. Go to original source... Go to PubMed...
- Vaverková H, Soška V, Rosolová H, et al. Doporučení pro diagnostiku a léčbu dyslipidémií v dospělosti, vypracované výborem České společnosti pro aterosklerózu. Vnitř Lék 2007;53:181-97. Go to PubMed...
- Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialist (CTT) Collaborators. Efficacy and safety of cholesterol lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005;366:1267-78. Go to original source... Go to PubMed...
- Cífková R, Býma S, Češka R, et al. Prevence kardiovaskulárních onemocnění v dospělém věku. Vnitř Lék 2005;51:1021-36.
- Keech A, Simes RJ, Barter P, et al. (FIELD study investigators). Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005;366:1849-61. Go to original source... Go to PubMed...
- Soška V. Poruchy metabolismu lipidů: Diagnostika a léčba. Praha: Grada, 2001.